Outlook Therapeutics (OTLK) Stock Statistics & Valuation Metrics

Outlook Therapeutics has a market cap or net worth of $26.16M. The enterprise value is $38.50M.

Outlook Therapeutics has 104,614,220 shares outstanding. The number of shares has decreased by -2.65% in one year.

Outlook Therapeutics’s return on equity (ROE) is 1.94 and return on invested capital (ROIC) is -2357.61%.

The current PE Ratio of Outlook Therapeutics is ―. Outlook Therapeutics’s PEG ratio is 0.01.

In the last 12 months, Outlook Therapeutics had revenue of 1.41M and earned -62.42M in profits. Earnings per share was -1.79.

In the last 12 months, operating cash flow was -14.94T and capital expenditures 0.00, giving a free cash flow of -14.94T billion.

Outlook Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Outlook Therapeutics upcoming earnings date is May 14, 2026, TBA (Confirmed).

Outlook Therapeutics as a current ratio of 0.38, with Debt / Equity ratio of -95.70%

In the past 12 months, Outlook Therapeutics has paid -1.55M in taxes.

Outlook Therapeutics EV to EBITDA ratio is -0.93, with an EV/FCF ratio of >-0.01.

Outlook Therapeutics has $8.68M in cash and marketable securities with $36.89M in debt, giving a net cash position of -$28.22M billion.

Gross margin is -588.66%, with operating margin of -4744.25%, and net profit margin of -4416.22%.

The average price target for Outlook Therapeutics is $3.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy